GUCY1B1 guanylate cyclase 1 soluble subunit beta 1
ENSG00000061918 · protein coding · Open Targets profile
Beta subunit of soluble guanylate cyclase (sGC), a key enzyme in nitric oxide (NO) signaling. sGC functions as a heterodimer consisting of one alpha and one beta subunit. It serves as the primary intracellular receptor for NO, which binds to a heme prosthetic group located on the beta subunit. Upon NO binding, sGC catalyzes the conversion of GTP into cyclic GMP (cGMP), thereby transmitting the NO signal into an ubiquitous intracellular second messenger. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, High-Quality Pocket, Druggable Family
- PROTAC
- Database Ubiquitination, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.6059799790382385 (upper bound 0.7814199924468994). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 386 registry trials, updated in the last three years, of the most advanced drugs against GUCY1B1 (nitroprusside, isosorbide dinitrate, pentaerythritol tetranitrate, methylene blue anhydrous, isosorbide mononitrate, riociguat, sodium nitroprusside, nitric oxide, nitroglycerin, vericiguat, ataciguat, olinciguat), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Lorenzo BerraAnesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital · 4 of 6 trials Phase 2+
- Keith MooreSanotize Research and Development corp. · 3 of 4 trials Phase 2+
- Michael K SticklandUniversity of Alberta · 3 of 3 trials Phase 2+
- Yunpeng ZhuRuijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China · 2 of 3 trials Phase 2+
- Chong LeiXijing Hospital · 2 of 2 trials Phase 2+
- Daniel S. BermanCedars-Sinai Medical Center · 2 of 2 trials Phase 2+
- Lacy M AlexanderPenn State University · 2 of 2 trials Phase 2+
- Mario FL GaudinoWeill Cornell Medicine NewYork Presbyterian Hospital · 2 of 2 trials Phase 2+
- Michael SticklandUniversity of Alberta · 2 of 2 trials Phase 2+
- Nikolay O KamenshchikovCardiology Research Institute, Tomsk National Research Medic · 2 of 2 trials Phase 2+
- Qiang ZhaoRuijin Hospital · 2 of 2 trials Phase 2+
- Amrita AhluwaliaQueen Mary University of London · 1 of 2 trials Phase 2+
- Peter S PangIndiana University · 1 of 2 trials Phase 2+
- Sean van DiepenUniversity of Alberta · 1 of 2 trials Phase 2+
- Aaron B WaxmanBrigham and Women's Hospital · 1 of 1 trials Phase 2+
Registry trials of nitroprusside, isosorbide dinitrate, pentaerythritol tetranitrate, methylene blue anhydrous, isosorbide mononitrate, riociguat, sodium nitroprusside, nitric oxide, nitroglycerin, vericiguat, ataciguat, olinciguat updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 341 of 363 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 23 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
161 trials of drugs against GUCY1B1 were stopped early; 10 give no reason
Terminated, withdrawn and suspended interventional trials of nitroprusside, isosorbide dinitrate, pentaerythritol tetranitrate, methylene blue anhydrous, isosorbide mononitrate, riociguat, sodium nitroprusside, nitric oxide, nitroglycerin, vericiguat, ataciguat, olinciguat, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 161.
- withdrawn · 2026-10-29 · Anna Stanhewicz, PhD · matched by the registry's drug synonyms“Trainee project; study never initiated”
- terminated · 2026-10-13 · Beyond Air Inc. · Nitric Oxide 25,000 ppm, Nitric Oxide 50,000 ppm“study stopped due to changes of sponsor strategy and resource allocation. No safety issues were identified”
- terminated · 2026-09-03 · Dr Sudarshan Rajagopal · Riociguat“Sponsor Requested”
- terminated · 2026-08-20 · Bayer · Riociguat (Adempas, BAY63-2521)“The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at the time the study was terminated.”
- terminated · 2026-06-17 · Heidelberg University · Riociguat“Strategic re-prioritization by the IMP supplier. Decision not safety-related”
- terminated · 2026-03-23 · Massachusetts General Hospital · Nitric Oxide“COVID wave passed”
- terminated · 2026-03-20 · Massachusetts General Hospital · Inhaled nitric oxide gas“COVID wave passed and we closed the study prematurely”
- suspended · 2026-03-18 · Instituto Nacional de Cardiologia Ignacio Chavez · Nitroglycerin 100 MCG/ML Injectable Solution“The sample was not completed.”
- withdrawn · 2026-03-18 · University of California, Los Angeles · inhaled nitric oxide (iNO)“no sponsor support”
- terminated · 2026-02-27 · Penn State University · Sodium Nitroprusside“Futility in recruitment”
- terminated · 2026-01-21 · Heidelberg University · Riociguat Oral Tablet“Strategic re-prioritization by the IMP supplier. Decision not safety-related.”
- terminated · 2025-12-30 · Beth Israel Deaconess Medical Center · Sodium Nitroprusside“Difficulty with recruiting subjects for the study”
- withdrawn · 2025-12-02 · Massachusetts General Hospital · Nitric Oxide“Lack of funding”
- withdrawn · 2025-12-02 · Massachusetts General Hospital · Nitric Oxide“Lack of funding”
- terminated · 2025-09-25 · Sanotize Research and Development corp. · Nitric Oxide“Recruitment challenges, i.e., not able to meet sample size targeted; secondary to the changing landscape of COVID-19 infection pathology.”
- withdrawn · 2025-09-17 · Ruijin Hospital · Oral isosorbide mononitrate 4+ amlodipine“Modify the trial design and construct a new larger trial.”
- terminated · 2025-08-20 · Montefiore Medical Center · matched by the registry's drug synonymsNo reason given
- terminated · 2025-08-03 · Queen Mary University of London · matched by the registry's drug synonyms“abandoned”
- terminated · 2025-07-15 · Thirty Respiratory Limited · matched by the registry's drug synonyms“Decision was made by the sponsor not to progress to Stage 2”
- terminated · 2025-05-11 · Peng Roc Chen, MD · Nicardipine + Verapamil + Nitroglycerin“Slow enrollment”
- terminated · 2025-04-08 · Colorado State University · Sodium Nitroprusside“IRB approval has been withdrawn”
- terminated · 2025-02-04 · Actelion · matched by the registry's drug synonyms“To be compliant with the timelines as agreed with Paediatric Committee (PC) within the Paediatric Investigational Plan”
- terminated · 2025-01-31 · Thirty Respiratory Limited · matched by the registry's drug synonyms“Study stopping criteria were met. A safety event has occurred which was classified as an SAE and was related to the study intervention.”
- terminated · 2025-01-20 · University of Nebraska · matched by the registry's drug synonyms“Unable to recruit sufficient number of subjects.”
- terminated · 2025-01-15 · AdventHealth · inhaled nitric oxide“based on DSMB recommendation at interim analysis”
Paediatric incentives and obligations for GUCY1B1's drugs
For nitroprusside, isosorbide dinitrate, pentaerythritol tetranitrate, methylene blue anhydrous, isosorbide mononitrate, riociguat, sodium nitroprusside, nitric oxide, nitroglycerin, vericiguat, ataciguat, olinciguat: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · GUCY1B1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001636-PIP01-14-M03 (vericiguat, Treatment of left ventricular failure): PM: decision on the application for modification of an agreed PIP, 28 Oct 2022; EMEA-002759-PIP01-19 (olinciguat, Treatment of sickle cell disease): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 22 Dec 2020; EMEA-000718-PIP01-09-M06 (riociguat, Treatment of pulmonary hypertension): PM: decision on the application for modification of an agreed PIP, 4 Nov 2016; compliance positive 11 Dec 2020; EMEA-000612-PIP01-09 (nitric oxide, Other pulmonary heart disease;Persistent Pulmonary Hypertension): W: decision granting a waiver in all age groups for all conditions or indications, 22 Dec 2009Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/07/518 withdrawn 20 Dec 2007: Treatment of pulmonary arterial hypertension; EU/3/15/1484 withdrawn 24 Apr 2015: Treatment of cystic fibrosis; EU/3/14/1299 withdrawn 29 Jul 2014: Treatment of systemic sclerosis; EU/3/15/1435 positive 12 Feb 2015: Treatment of systemic sclerosis; +2 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Riociguat Accord: opinion; Adempas: authorised since 27 Mar 2014; Verquvo: authorised since 16 Jul 2021; INOmax: authorised since 1 Aug 2001Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of nitroprusside, isosorbide dinitrate, pentaerythritol tetranitrate, methylene blue anhydrous, isosorbide mononitrate, riociguat, sodium nitroprusside, nitric oxide, nitroglycerin, vericiguat, ataciguat, olinciguatRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 209 interventional studies of nitroprusside, isosorbide dinitrate, pentaerythritol tetranitrate, methylene blue anhydrous, isosorbide mononitrate, riociguat, sodium nitroprusside, nitric oxide, nitroglycerin, vericiguat, ataciguat, olinciguat include patients under 18; 26 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 15 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.